论文部分内容阅读
目的调查分析四川泸县地区不同宫颈病变患者人类乳头状瘤病毒(Human Papilloma Virus,HPV)感染情况,为该地区HPV感染的预防和宫颈癌筛查防治提供参考。方法采用基因芯片技术对宫颈液基细胞技术所获宫颈细胞及手术切除宫颈石蜡组织进行基因分型检测,统计HPV各基因型的感染及分布情况。结果 275例宫颈病变样本中,HPV检出阳性率为53.09%(146/275),其中高危感染占84.25%(123/146),低危感染占30.14%(44/146),单一感染占88.36%(129/146),混合型占11.64%(17/146)。高危型中最常见前6种亚型依次为:HPV16、39、58、52、18和66,低危型中最常见前4种亚型依次为:HPV11、6、54和44。总感染率中表现出两个年龄分布高峰,20~29岁和50~70岁年龄段。高危型感染在各年龄段没有显著差异,低危型感染主要集中在20~29岁,显著高于其余各年龄段(P<0.01)。结论泸县地区不同程度宫颈病变患者有较高的高、低危型HPV感染率,具有较强的区域和年龄段分布特点。本研究可为该地区HPV感染的预防和宫颈癌筛查防治及疫苗使用等提供重要的参考依据。
Objective To investigate and analyze the human papilloma virus (HPV) infection in patients with different cervical lesions in Luxian County, Sichuan Province, and to provide reference for the prevention of HPV infection and prevention and treatment of cervical cancer in this area. Methods Genomic microarray technique was used to genotype cervical cells from cervical liquid-based cells and excision of cervical paraffin tissue. The infection and distribution of HPV genotypes were statistically analyzed. Results Among 275 cervical lesions, the positive rate of HPV was 53.09% (146/275), of which 84.25% (123/146) were high-risk infections, 30.14% (44/146) were low-risk infections and 88.36 % (129/146), mixed accounted for 11.64% (17/146). The most common top six subtypes of high risk type were HPV16,39,58,52,18 and 66 respectively. The most common first four subtypes of low risk type were HPV11,6,54,44. The total infection rate showed two age distribution peaks, 20 to 29 years and 50 to 70 years of age. There was no significant difference in high-risk infection among all age groups. Low-risk infection mainly concentrated in 20-29 years old, which was significantly higher than the other age groups (P <0.01). Conclusion There is a high prevalence of HPV infection in high and low risk HPV genotypes in patients with varying degrees of cervical lesions in Luxian County, with strong regional and age distribution. This study may provide an important reference for the prevention of HPV infection and the prevention and control of cervical cancer screening and vaccine use in this area.